Delivery Order SPE2DB22D3301-SPE2DB25FY5PU
- Not listed
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Xolair 150 mg/mL syringes, with completion targeted for July 21, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the federal...
- The Defense Logistics Agency awarded a $2,161.02 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xolair 150 mg/ml syringes, with completion scheduled for May 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. The contract, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, was awarded on a non-competitive, firm fixed-price basis. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Xolair 150 mg/ml syringes, with a firm fixed price ceiling value of $6,483.06 and an ultimate completion date of June 24, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under the company's larger pharmaceutical supply framework with the federal government. The place of performance is listed as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,376.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on May 2, 2025, with completion scheduled for May 23, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $30,254.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of July 10, 2025. This non-set-aside contract was competitively awarded on June 17, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a Delivery Order valued at $1,440.70 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under a larger indefinite delivery contract vehicle. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $5,762.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xolair 150 mg/ml syringes. This non-competitive delivery order, which must be completed by May 15, 2025, represents a child task order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The delivery will be performed at AmerisourceBergen's...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY5PUDelivery Order
The Defense Logistics Agency awarded a $34,576.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xolair 150 mg/ml syringes. This non-set-aside competitive award is scheduled for completion by June 24, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company maintains extensive federal contract relationships with DLA and other government healthcare entities. This delivery order is issued under AmerisourceBergen's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Xolair (omalizumab), a monoclonal antibody used in the treatment of moderate to severe allergic asthma and other allergic conditions, represents a specialized pharmaceutical commodity within the company's extensive therapeutic portfolio delivered to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.6k | 6/2/25 |